Company / Operating Income
VYNE Therapeutics Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$43.6M
FY2025
5-year range
-$252.5M / -$29.3M
FY2021-FY2025
Trend
-49.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$34M to -$44M over the past 2 years.
Based on SEC 10-K filings.
-$44M in FY2025.
Declined from -$34M to -$44M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 49.1% year-over-year.
- Peak operating income was recorded in FY2018.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$43.6M | -49.1% |
| FY2024 | -$29.3M | +14.7% |
| FY2023 | -$34.3M | +11.9% |
| FY2022 | -$38.9M | +84.6% |
| FY2021 | -$252.5M | -237.2% |
| FY2020 | -$74.9M | -153.1% |
| FY2019 | -$29.6M | -106.5% |
| FY2018 | -$14.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026